Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Journey Medical CorporationNASDAQ: DERM

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $989K fell 25.2% year over year, behind the -1.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 44.3% from the prior quarter. Over 3 fiscal years it compounded at +12.4% a year.

Context

  • Stock-based compensation amounted to 10.2% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -25.2% toward the trailing-twelve-month pace of -1.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$989K-44.3% QoQ
Last fiscal yearDec 2025
$6.29M+3.1% YoY
LTMMar 2026
$5.95M-1.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.2%——
1 year+3.1%——
3-year CAGR+12.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.29M USD
Year-over-year change
+3.1%
4-year CAGR
+26.4%

Stock-Based Compensation vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.0% is the 6th highest of 10, against a peer median of +7.9%.
  • Stock-based compensation amounts to 9.2% of revenue for DERM, versus a peer median of 20.1%.
DERM Competitors
Stock-Based Compensation for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$11.86M USD+7.9%+52.0%36.3%
OSUROraSure Technologies, Inc.LTM Mar 2026$11.45M USD-1.6%-90.4%10.1%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$10.44M USD+36.3%-2.0%587.9%
HSDTSolana CompanyLTM Mar 2026$8.72M USD+217.8%—90.9%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$6.24M USD+33.6%+18.6%12.2%
DERMJourney Medical CorporationLTM Mar 2026$5.95M USD-1.0%+12.4%9.2%
OGIOrganigram Global Inc.LTM Mar 2026CA$3.45M CAD-36.6%—1.3%
MDWDMediWound Ltd.LTM Mar 2026$2.91M USD-16.2%+16.9%20.1%
NYXHNyxoah S.A.LTM Mar 2026€887K EUR-82.2%—5.4%
Peer median (excluding DERM) —+7.9%+17.7%20.1%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Depreciation & Amortization2.56M4.37M3.86M3.42M4.72M
Deferred Income Tax1.57M0000
Stock-Based Compensation2.47M4.43M2.61M6.1M6.29M
Change in Working Capital14.71M6.19M(1.66M)(3.77M)(11.9M)
Accounts Receivables768K(5.38M)12.55M4.48M(19.34M)
Inventory(8.46M)1.74M3.95M(4.23M)4.81M
Accounts Payables21.71M14.34M(18.42M)(2.1M)(7.27M)
Other Working Capital686K(4.52M)262K(1.92M)9.91M
Other Non-Cash Items20.51M1.12M4.29M(211K)(123K)
Operating Cash Flow(2.18M)(13.53M)5.24M(9.13M)(12.44M)
Capital Expenditures(10M)(20M)(5M)(15M)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(10M)(20M)(5M)(15M)0
Debt Repayment5.05M16.9M(8.95M)8.7M15.73M
Common Stock Issued32.54M142K4.49M8.29M16.93M
Common Stock Repurchased0(371K)000
Dividends Paid00000
Other Financing Activities16.97M(214K)(350K)(50K)(16.43M)
Financing Cash Flow53.02M16.46M(4.8M)16.99M16.23M
Effect of Forex Changes00000
Net Change in Cash40.84M(17.08M)(4.56M)(7.13M)3.79M
Free Cash Flow(12.18M)(33.53M)240K(9.13M)(12.44M)

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.